XTL Bio
Manufacturing · Israel · 1-10 Employees
View Company Info for Free
Overview
Headquarters
5 Badner St. P.o.box 8241, Ramat Gan, Te...Phone Number
+972 99557080Website
www.xtlbio.comRevenue
<$5 MillionStock Symbol
XTLBIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About XTL Bio
XTL Biopharmaceuticals is a clinical-stage biotechnology company focused on the development of innovative pharmaceutical treatments for autoimmune diseases, with a particular emphasis on systemic lupus erythematosus. The company is dedicated to advancing novel therapeutic solutions designed to address unmet medical needs in conditions where existing treatments often provide limited effectiveness or are associated with significant side effects. Its work is centered on translating scientific research into potential clinical therapies that can improve patient outcomes and quality of life.Explore more
XTL Bio Org Chart
NS
Chief Financial Officer
IW
Chief Financial Officer
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is XTL Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on XTL Bio recently announced quarterly report
XTL Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if XTL Bio had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once XTL Bio has new funding data
Product Launch: Get notified when XTL Bio launches new products
Congratulate Masked Content for being promoted to Masked Content at XTL Bio
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if XTL Bio has recently received funding, and reach out quickly before it becomes old news!
Check out if XTL Bio is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined XTL Bio as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
XTL Bio is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
XTL Bio is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about XTL Bio.
XTL Bio Tech Stack
A closer look at the technologies used by XTL Bio
Most Recent Scoops
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
New Hire
Executive Move
Executive Moves, New Hire
Executive Move
Executive Moves, Board of Directors
New Hire
Executive Move
Executive Moves, New Hire
XTL Bio News & Media
XTL Announces Receipt of Staff Delist Determination from Nasdaq
RAMAT GAN, ISRAEL, May 22, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced today that it has received a letter (the “Letter”) from The Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”), dated May 18, 2026, notifying the Company that since the Company has not yet filed its Annual Report on Form 20-F for the year ended December 31, 2025, it no longer complies withXTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies
Transaction Positions XTL at the Forefront of the Rapidly Expanding Global Psychedelic Therapeutics Market Following Major U.S. Regulatory MomentumXTL Biopharmaceuticals Announces ADS Ratio Change
RAMAT GAN, ISRAEL, March 20, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced today that it plans to change the ratio of its American Depositary Shares ("ADSs") to its ordinary shares, par value NIS0.1 per share (the "ADS Ratio"), from the current ADS Ratio of one (1) ADS to one hundred (100) ordinary shares, to a new ADS Ratio of one (1) ADS to four hundred (400) ordinary shares (the "ADSBeyond Air® Announces Termination of Agreement to Sell Its NeuroNOS Subsidiary to XTL Biopharmaceuticals Ltd.
GARDEN CITY, N.Y., March 10, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that the previously disclosed proposed transaction with XTL Biopharmaceuticals Ltd. (“XTL”) relating to Beyond Air’s NeuroNOS subsidiary has been terminated.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding XTL Bio
Sign Up For FreeTo access detailed company insights
XTL Biopharmaceuticals is a clinical-stage biotechnology company focused on the development of innovative pharmaceutical treatments for autoimmune diseases, with a particular emphasis on systemic lupus erythematosus. The company is dedicated to advancing novel therapeutic solutions designed to address unmet medical needs in conditions where existin... Read More
